James F. Szigethy Named Curemark’s Director of New Product Development
RYE, N.Y., Sept. 7 /PRNewswire/ — Curemark (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that James F. Szigethy, formerly a consultant for Curemark, has assumed the position of Director of New Product Development. In his new position, Szigethy will have direct oversight of improving existing products and directing the development of new products. As Curemark continues to anticipate expansion of its clinical trials program, Szigethy will oversee and coordinate all activities across a variety of Curemark product programs, the company said.
Dr. Joan Fallon, Curemark’s Founder and CEO said, “We are very excited to have James assume this new position. Curemark has a strong focus on innovation coupled with excellence and James’ credentials as an experienced pharmacist and consultant are a tremendous asset to us.”
“I am excited to have the opportunity to implement Curemark’s strategic vision and this is a truly exciting company to work for,” remarked Szigethy. “Curemark is focused on children with conditions for whom either no treatment or inadequate treatment is available and I am proud to be at the forefront of the development of new products to further our studies and Curemark’s mission.”
Szigethy’s new responsibilities will include formulation development, overseeing Curemark’s product production and expansion of its product portfolio. He has been with the company since 2007.
Szigethy graduated from St. John’s University in 1994 with a B.A. in Psychology. He attained his B.S. in Pharmacy in 2001 and became a supervising pharmacist for Wal-Mart, where his department was recognized as Wal-Mart’s Northeast Region Pharmacy of the Year in 2006.
Curemark currently is conducting Phase III clinical trials for CM-AT, an autism treatment that will be one of the first to address the underlying physiology of autism. CM-AT is based on Dr. Fallon’s breakthrough research that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein. The inability to digest protein affects the production of amino acids, the building blocks of chemicals essential for brain function. The FDA has designated CM-AT as a Fast Track drug.
About CUREMARK LLC
Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company’s initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com
Safe Harbor Statement
This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.
SOURCE Curemark LLC